Neurontin CNS Trials Will Speed Development Of Successor Product
Executive Summary
Trials of Warner-Lambert's Neurontin (gabapentin) in non-epilepsy indications will facilitate rapid development of its follow-on compound pregabalin, the company told securities analysts at an R&D update meeting April 21 in New York City.